CVS vs GRDN
CVS: A leading health solutions company integrating retail pharmacy, pharmacy benefit management, and insurance services to manage health costs and improve access to care. GRDN: Guardian Pharmacy Services provides specialized pharmacy and medication management solutions for long-term care facilities.
Side-by-side fundamentals
| Metric | CVS | GRDN | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $93.45 | $38.98 | |
| Market cap | $119.5B | $2.5B | |
| P/E as of 2026-10-21 | 24.66 | 37.48 (diluted EPS of the listed share class, as reported in the 10-Q/10-K) | CVS lower |
| Net margin FY2025, SEC XBRL | +0.4% | +3.4% | GRDN higher |
| Gross margin FY2025, SEC XBRL | n/a | +20.2% | |
| Operating margin FY2025, SEC XBRL | +1.2% | +5.0% | GRDN higher |
| ROE FY2025, SEC XBRL | +2.4% | +22.6% | GRDN higher |
| ROA FY2025, SEC XBRL | +0.7% | +11.9% | GRDN higher |
| Debt / equity filed borrowings incl. finance leases, balance sheet 2026-06-30 | 0.77 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +7.8% | +17.9% | GRDN higher |
| Revenue CAGR (3y) SEC XBRL | +7.6% | n/a | |
| Dividend yield as of 2026-09-03 | +3.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | CVS higher |
| Beta as of 2026-09-03 | 0.28 | 0.69 | |
| 1-year return as of 2026-10-21 close | +12.5% | +44.1% | GRDN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.